XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Discontinued Operations
 6 Months Ended
Jul. 01, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations DISCONTINUED OPERATIONS
On December 31, 2021, the Company completed the sale of substantially all of the KaVo Treatment Unit and Instrument Business (the “Divestiture”) to planmeca Verwaltungs Gmbh, Germany (“Planmeca”), pursuant to the master sale and purchase agreement (the “Purchase Agreement”) among the Company, Planmeca, and Planmeca Oy, as guarantor. In accordance with the terms of the Purchase Agreement, the Company received cash consideration of $317.3 million upon closing, which remains subject to certain adjustments. In addition, the Company received an earnout payment of $30.0 million during the first six months of 2022.

On December 30, 2021, the Company entered into an amendment to the Purchase Agreement (the "Amendment"), providing that the transfer of net assets in Russia, China and Brazil (the "Relevant Jurisdictions") will be deferred until the purchaser has formed entities for such transfer of assets in each such Relevant Jurisdiction and the applicable asset transfer agreement can be executed and consummated (each such asset transfer, a "Deferred Local Closing"). Except for the implementation of the Deferred Local Closings and related matters regarding the assets in the Relevant Jurisdictions, the provisions, terms and conditions of the Purchase Agreement were not materially amended by the Amendment. The Amendment did not alter the preliminary purchase price that Planmeca paid to the Company upon the closing of the Divestiture. The Company recognized a liability of $4.0 million and$10.8 million for the proceeds related to the Relevant Jurisdictions as of July 1, 2022, and December 31, 2021, respectively. The Company will recognize the applicable gain or loss at the time of each Relevant Jurisdiction’s applicable closing. As of July 1, 2022, one of the Relevant Jurisdictions has closed. The remaining Relevant Jurisdictions are expected to close at various points throughout 2022.

The Company recognized a gain of $2.7 million and $7.3 million on the Divestiture during the three and six months ended July 1, 2022, respectively, primarily due to the recognition of certain purchase price adjustments and the closing of one of the Relevant Jurisdictions.

In conjunction with the Divestiture, the Company entered into a customary transition services agreement, which requires support transition services to Planmeca throughout the applicable transition period.

For the three and six months ended July 1, 2022, the Divestiture continued to meet the criteria to be classified as held for sale and to be presented as a discontinued operation. Accordingly, the Company reclassified the results of operations and financial position of the Divestiture to discontinued operations in its accompanying Condensed Consolidated Statements of Income and Condensed Consolidated Balance Sheets for all periods presented. The Company’s Condensed Consolidated Statements of Cash Flows for all periods presented include the financial results of the KaVo Treatment Unit and Instrument Business.
For the six months ended July 2, 2021, balances represent activity for the entire Divestiture, while balances for the six months ended July 1, 2022, represent activity for the remaining Relevant Jurisdictions.

The carrying amounts of the assets and liabilities of the Divestiture held for sale are as follows ($ in millions):
As of
July 1, 2022December 31, 2021
ASSETS
Current assets:
Assets for relevant jurisdictions$4.1 $12.2 
Current assets held for sale$4.1 $12.2 
LIABILITIES AND EQUITY
Current liabilities:
Liabilities for relevant jurisdictions$1.7 $4.0 
Current liabilities held for sale$1.7 $4.0 
The operating results of the Divestiture are reflected in the Condensed Consolidated Statements of Income within income from discontinued operations, net of tax as follows ($ in millions):
 Three Months EndedSix Months Ended
 July 1, 2022July 2, 2021July 1, 2022July 2, 2021
Sales$2.0 $102.9 $8.9 $199.5 
Cost of sales1.1 59.6 7.0 117.3 
Gross profit0.9 43.3 1.9 82.2 
Operating expenses:
Selling, general and administrative1.0 23.7 2.1 45.1 
Research and development— 4.4 — 8.7 
Operating (loss) profit(0.1)15.2 (0.2)28.4 
Income tax expense— 4.1 7.4 
(Loss) income from discontinued operations(0.1)11.1 (0.2)21.0 
Gain on sale of discontinued operations, net of tax2.7 — 7.3 — 
Net income from discontinued operations$2.6 $11.1 $7.1 $21.0 

Significant non-cash operating items and capital expenditures for the Divestiture are reflected in the cash flows from operations as follows ($ in millions):
Six Months Ended
July 1, 2022July 2, 2021
Cash flows from operating activities
Depreciation and amortization1
$— $3.3 
Cash flows from investing activities:
Capital expenditures$— $2.4 
1 Depreciation and amortization were no longer recognized once the business was classified as discontinued operations as of August 27, 2021.